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Introduction: In the phase III AVAPERL trial, patients with 
advanced nonsquamous non–small-cell lung cancer receiving beva-
cizumab-plus-pemetrexed maintenance after first-line induction had 
a significant progression-free survival benefit relative to those treated 
with single-agent bevacizumab maintenance but with an increase in 
grade ≥3 adverse events. Here, we compare health-related quality of 
life (HRQOL) between AVAPERL maintenance arms.
Methods: Patient-reported outcomes were collected at designated 
intervals from preinduction to final visits. HRQOL was assessed 
using the self-administered European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30 and the 
Quality of Life Lung Cancer–Specific Module 13. Differences in 
scores of 10 points or more between arms were above the minimum 
important difference threshold and considered clinically meaningful.
Results: During induction, patient-reported coughing symptoms 
improved slightly, whereas fatigue and appetite loss scores worsened 
relative to preinduction baseline. During maintenance, changes in mean 
global health status and the majority of Quality of Life Questionnaire 
Core 30 and Quality of Life Lung Cancer–Specific Module 13 sub-
scale scores did not differ between trial arms by the minimum important 
difference defining clinically meaningful (better or worse) patient-
reported outcomes. Exceptions were patient-reported role functional 
status, fatigue symptoms and appetite loss symptoms (favoring bevaci-
zumab), and pain in arm or shoulder symptoms (favoring bevacizumab-
plus-pemetrexed maintenance), which differed by clinically meaningful 
amounts at more than one maintenance assessment.
Conclusions: In AVAPERL, HRQOL remained relatively stable 
throughout maintenance and was generally similar in both arms. 
Despite an increase in adverse event rates, the addition of pemetrexed 
to bevacizumab maintenance resulted in similar stabilization of dis-
ease symptoms with improved efficacy outcomes.
Key Words: Patient-reported outcomes, Non–small-cell lung cancer, 
Bevacizumab, Pemetrexed, AVAPERL, Maintenance.
(J Thorac Oncol. 2013;8: 1409–1416)
Although advances in first- and second-line treatments have improved survival outcomes in patients with stage IIIb 
or stage IV non–small-cell lung cancer (NSCLC), therapy 
remains palliative rather than curative.1 Advanced NSCLC 
is associated with a significant burden from disease-related 
symptoms.2–4 Improvement of disease symptoms, the effect 
of treatment-related adverse events, and health-related quality 
of life (HRQOL) are important factors when evaluating any 
treatment regimen in NSCLC and will only become more crit-
ical as improved treatment options further extend survival.5.6
Promising advances in NSCLC treatment include 
the targeting of specific genetic mutations present in some 
tumors, such as the anaplastic lymphoma kinase gene, as well 
as activating mutations of the epidermal growth factor recep-
tor.7,8 These are absent, however, in most patients who are 
likely agnostic for targetable mutations. In addition, obtaining 
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biopsy samples to determine mutational status is not always 
possible because of tumor location, and it remains far from 
clear whether a single biopsy taken from one tumor reflects 
the underlying genotype of that tumor or, by extension, of all 
tumors present.9 For these reasons, improvements in systemic 
chemotherapy regimens remain essential to improving clinical 
outcomes for most patients with NSCLC.
Maintenance therapy following first-line induction is a 
broadly applicable approach to improve survival in advanced 
NSCLC. Continuation and switch maintenance therapies 
are potential strategies to augment the benefit of first-line 
therapy and are currently recommended as treatment options 
for patients with advanced NSCLC.1,10,11 The anti–vascular 
endothelial growth factor monoclonal antibody bevacizumab 
and the antifolate agent pemetrexed have both proven to be 
important components in first-line induction regimens,12–14 
and accumulating evidence also supports their value in the 
maintenance setting. Phase III clinical trials have demon-
strated the benefit of pemetrexed maintenance relative to 
placebo after platinum- or pemetrexed-based chemotherapy 
induction.15,16 Recent meta-analyses17,18 and exploratory 
analyses19–21 have also associated maintenance treatment 
using bevacizumab with improved outcomes for patients 
with NSCLC.
Although continuation or switch maintenance appears 
to be important, few phase III trials have directly compared 
maintenance phase regimens.22 One that did was the phase III 
AVAPERL (MO22089) trial, which compared bevacizumab 
plus pemetrexed with single-agent bevacizumab maintenance 
in patients with previously untreated advanced NSCLC who 
had achieved stable disease (SD) or partial response (PR) 
following four cycles of bevacizumab-cisplatin-pemetrexed 
induction. Combination maintenance therapy resulted in 
improved progression-free survival (PFS) compared with sin-
gle-agent bevacizumab maintenance. The median PFS as mea-
sured from randomization was 7.4 versus 3.7 months (hazard 
ratio [HR] = 0.48 [95% confidence interval (CI), 0.35–0.66]; 
p < 0.001); as measured from induction, median PFS values 
were 10.2 versus 6.6 months (HR = 0.50 [95% CI, 0.37–0.69]; 
p < 0.001).23 At a median follow-up time of 14.8 months, 
median overall survival from induction was numerically lon-
ger in the bevacizumab-plus-pemetrexed arm (19.8 versus 
15.9 months (HR = 0.88 [95% CI, 0.64–1.22], p = 0.32).24 
Throughout the study, patients in the bevacizumab-plus-
pemetrexed arm had a higher incidence of grade ≥3 adverse 
events and serious adverse events.25 The most common 
grade ≥3 adverse events with onset in maintenance were 
hypertension and dyspnea (2.5% each) in the bevacizumab 
arm and neutropenia (5.6%), hypertension (4.8%), and ane-
mia (3.2%) in the bevacizumab-plus-pemetrexed arm.
The observation of improved PFS, as well as an 
increase in adverse events associated with bevacizumab-
plus-pemetrexed maintenance, underscores the importance 
of a comparative analysis of HRQOL in the maintenance 
arms of this study. Here we examine in detail the patient-
reported HRQOL results from preinduction baseline 
through maintenance cycle 11, focusing on a compari-
son of changes in mean scores between trial arms for six 
patient-reported symptoms related to lung cancer treat-
ment, five functional subscales, and global health status 
during maintenance.
MATERIALS AND METHODS
Eligibility and Treatment
Details of the AVAPERL study methodology and 
results were previously published.23 Briefly, key inclusion cri-
teria were documented stage IIIB or IV or recurrent NSCLC 
with one or more lesions measurable by Response Evaluation 
Criteria in Solid Tumors v1.1, as well as an Eastern 
Cooperative Oncology Group performance status (ECOG 
PS) of 0, 1, or 2 at preinduction baseline. Patients with prior 
systemic treatment for lung cancer, a history of hemoptysis, 
or predominantly squamous cell histology were excluded. In 
the first part of the study, patients received induction therapy 
with bevacizumab (7.5 mg/kg intravenously [IV]), cispla-
tin (75 mg/m2 IV), and pemetrexed (500 mg/m2 IV) every 3 
weeks (q3w) for four cycles. Throughout the trial, patients 
treated with pemetrexed received supplemental/prophylactic 
treatment with folic acid, vitamin B
12
, and dexamethasone. 
Patients were assessed using Response Evaluation Criteria 
in Solid Tumors v1.1; those with complete response, PR, or 
SD after induction were eligible for the maintenance phase 
of the study. Follow-up continued for those with progressive 
disease. In the maintenance phase of AVAPERL, patients 
were randomized 1:1 to the bevacizumab monotherapy arm 
(7.5 mg/kg IV q3w) or the bevacizumab-plus-pemetrexed 
arm (bevacizumab, 7.5 mg/kg IV; pemetrexed, 500 mg/m2 
IV q3w). Maintenance treatment continued until one of the 
following: disease progression, unacceptable toxicity, with-
drawal of consent, or death.
Patient-Reported Outcomes
The impact of disease- and treatment-related symp-
toms on HRQOL was assessed using the self-administered 
European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC 
QLQ-C30) questionnaire (QLQ-C30) version 3.0 and the 
associated EORTC Quality of Life Lung Cancer–Specific 
Module (EORTC QLQ-LC13).26,27 Questionnaires were 
distributed and collected at preinduction baseline, prior to 
induction cycle 3 (week 6), at the postinduction response 
assessment (week 12), prior to maintenance cycle 1 (during 
weeks 11–13), every two cycles thereafter, at every follow-
up visit, and at the final visit. Patients completed validated 
questionnaires in their local language. Questionnaires were 
scored based upon the EORTC scoring guidelines.28 Mean 
scores for each of the QLQ-C30 and QLQ-LC13 subscales 
at each assessment from preinduction baseline to main-
tenance cycle 11 were calculated. Because of the small 
numbers of completed questionnaires available for later 
maintenance cycles (<40), these have not been included 
in the current analysis. For the maintenance phase of the 
study, changes in mean scores relative to premaintenance 
baseline for patients in each arm at maintenance cycles 3 
through 11 were also calculated.
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Included in the present analysis is the graphical pre-
sentation of mean scores for global health status, all five 
EORTC QLQ-C30 functional domains, and six symptom 
scales from the EORTC QLQ-C30 and QLQ-LC13 instru-
ments, which include those considered most distressing by 
patients with lung cancer (e.g., cough, dyspnea, chest pain, 
appetite loss, and fatigue).29,30 Data for other QLQ-C30 and 
QLQ-LC13 subscales are presented in Supplemental Table 
1 (Supplemental Digital Content 1, http://links.lww.com/
JTO/A462) and Supplemental Figures 1 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A463) and 
2 (Supplemental Digital Content 3, http://links.lww.com/
JTO/A464).
Statistical Methods
For the secondary trial end point of HRQOL, the objec-
tive was to detect and compare changes in EORTC QLQ-C30 
and QLQ-LC13 subscale scores between the two treatment 
arms over the duration of the study. HRQOL analyses were 
based on an intent-to-treat (ITT) population, which was 
defined as all screened patients who were randomized to a 
maintenance arm. The frequency and percentage of miss-
ing data were calculated. The percentage of compliance was 
calculated as the number of completed assessments divided 
by the number of patients still on study in each arm at the 
measurement time point. Scores were only calculated if at 
least 50% of the items from the scale had been completed. 
Differences in any scores of ≥10 points were considered clini-
cally meaningful.31
RESULTS
Patient and Disease Characteristics
A total of 414 patients were screened at 82 centers; 376 
patients were enrolled, and 373 patients received induction. 
Some 253 patients were randomized to maintenance treat-
ment. The ITT populations consisted of 125 patients in the 
bevacizumab arm and 128 patients in the bevacizumab-plus-
pemetrexed arm. Patient and disease characteristics at prein-
duction baseline were similar for patients later randomized 
to both maintenance arms, with the exception of ECOG PS, 
for which a higher percentage of patients later randomized to 
bevacizumab-plus-pemetrexed maintenance had a score of 0 
(52.4% versus 42.7%).23 At premaintenance, baseline patient 
and disease characteristics, including ECOG PS (33.7% and 
31.7% of patients having ECOG PS 0 in the bevacizumab-
plus-pemetrexed and bevacizumab arms, respectively), were 
similar for both arms.
Questionnaire Completion Rates
Distribution and completion rates for the EORTC ques-
tionnaires are shown in Table 1. An imbalance in distribution 
rates was noted at all maintenance cycle time points, with 
questionnaires consistently being distributed at higher rates 
to patients randomized to the bevacizumab-plus-pemetrexed 
arm. Patients in both arms returned questionnaires at similar 
high rates (94.5%–100%).
Patient-Reported Induction and 
Maintenance Phase Outcomes
All QLQ-C30 and QLQ-LC13 subscales in which 
there were any clinically meaningful (≥10 point) changes 
from premaintenance baseline values in either trial arm dur-
ing maintenance cycles 3 through 11 are listed in Table 2. 
Mean scores for global health and all QLQ-C30 functional 
scales from preinduction baseline through maintenance cycle 
11 are shown in Figure 1. Mean subscale scores from the 
QLQ-C30 and the QLQ-LC13 questionnaires for six symp-
toms deemed to be most relevant for lung cancer patients 
from preinduction baseline through maintenance cycle 11 
are shown in Figure 2.
Induction phase treatment was identical for patients 
who were later randomized to each of the treatment arms. 
However, there was a slight imbalance in global health and 
physical functional scores at premaintenance baseline, with 
mean scores for these scales being higher among patients ran-
domized to the bevacizumab-plus-pemetrexed arm (Fig. 1). 
These differences, however, did not reach the minimum 
important difference. Over the course of induction therapy 
TABLE 1.  Compliance with Quality-of-Life Assessments in AVAPERL
Bevacizumab Bevacizumab + Pemetrexed
Patients on 
Study, No.
Distributed, 
No. (%)a
Completed, 
No. (%)b
Patients on 
Study, No.
Distributed, 
No. (%)a
Completed 
(%)b
Preinduction BL 125 121 (96.8) 118 (97.5) 128 126 (98.4) 121 (96.0)
Induction cycle 3 125 117 (93.6) 111 (94.9) 128 115 (89.8) 114 (99.1)
Premaintenance BL 120 119 (99.2) 119 (100) 125 125 (100) 124 (99.2)
Maintenance cycle 3 110 73 (66.4) 69 (94.5) 120 87 (72.5) 87 (100)
Maintenance cycle 5 83 52 (62.7) 50 (96.2) 98 81 (82.7) 77 (95.1)
Maintenance cycle 7 56 39 (69.6) 38 (97.4) 75 66 (88.0) 64 (97.0)
Maintenance cycle 9 48 33 (68.8) 33 (100) 59 52 (88.1) 50 (96.2)
Maintenance cycle 11 35 25 (71.4) 25 (100) 47 39 (83.0) 37 (94.9)
aBased on the number of on-study patients in the arm.
bBased on the number of questionnaires distributed.
BL, baseline.
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cough decreased relative to preinduction baseline, indicat-
ing a slight improvement in patient status. On the other hand, 
patient-reported fatigue and appetite loss showed a trend 
toward worsening during induction (Fig. 2).
Patient-reported mean role functional and social func-
tional scores were higher for patients in the bevacizumab arm 
at each maintenance cycle. However, in evaluating changes 
from premaintenance baseline values the differences between 
trial arms were clinically meaningful only for role functional 
scores at cycles 7, 9, and 11 (Table 2). Over the course of 
maintenance therapy mean scores for cough and pain in chest 
symptoms were stable and similar between arms, median 
patient-reported fatigue scores improved slightly in both arms, 
and dyspnea scores increased in the bevacizumab-plus-peme-
trexed arm relative to premaintenance baseline. However, the 
differences between the trial arms in their respective changes 
from premaintenance baseline levels did not reach the clini-
cal relevance threshold for any of these patient-reported out-
comes (PROs; Table 2).
At four of the five maintenance phase assessments, 
mean scores for pain in arm or shoulder symptoms were 
higher in the bevacizumab arm, with clinically meaningful 
differences between arms in changes from premaintenance 
baseline levels favoring the bevacizumab-plus-pemetrexed 
arm at cycles 9 and 11. Mean appetite loss symptom scores 
decreased from premaintenance baseline levels by clinically 
meaningful amounts (range, 10.3–20.8 points) at all mainte-
nance phase assessments among patients in the bevacizumab 
group, but it did not decrease from premaintenance base-
line levels by a clinically meaningful amount (range, 6.1 
to −0.5 points) at any maintenance assessment among patients 
treated with bevacizumab plus pemetrexed (Table 2); the dif-
ference in changes between trial arms favored the bevaci-
zumab arm by clinically meaningful amounts at cycles 7, 9, 
and 11 (Table 2).
DISCUSSION
In the absence of curative therapy, HRQOL is a critically 
important aspect of any new treatment for advanced NSCLC. 
Although physician-reported adverse event collection is used 
to objectively evaluate disease- and symptom-related toxici-
ties, only PROs reflect the symptom burdens and functional 
status changes as directly experienced by patients. As a result, 
HRQOL is increasingly incorporated as a secondary endpoint 
in NSCLC trials.32–34 A real-world study of the importance to 
patients of symptom palliation—directly assessed via PROs—
found that 68% of patients previously treated for advanced 
NSCLC with first-line platinum-based chemotherapy would 
choose chemotherapy, even with no survival benefit, over sup-
portive care if it substantially reduced symptoms.35,36 HRQOL 
for patients with NSCLC treated with maintenance phase 
bevacizumab or pemetrexed is now being investigated in a 
number of phase III trials, including AvaALL (MO22097),37 
PointBreak,38 and ERACLE.39
In AVAPERL, induction phase therapy was associated 
with relatively stable functional scores. An initial imbalance 
TABLE 2.  All EORTC QLQ-C30 and QLQ-LC13 Items Showing a Clinically Meaningful (≥10 point) Change from 
Premaintenance Baseline Values in Either Maintenance Arm
Questionnaire Item
MTC 3 MTC 5 MTC 7 MTC 9 MTC 11
Favors
BV BV + P
Δa
BV BV + P
Δa
BV BV + P
Δa
BV BV + P
Δa
BV BV + P
ΔaN = 69 N = 87 N = 51 N = 77 N = 38 N = 64 N = 33 N = 50 N = 25 N = 37
QLQ-C30 Role  
functioning
5.9 1.3 −4.5 7.8 −1.9 −9.8 18.0 −2.3 −20.3 16.2 −4.7 −20.8 18.7 −2.7 −21.4 BV
Fatigue  
symptoms
−7.0 −6.3 0.8 −6.1 −4.5 1.6 −11.0 −2.6 8.4 −12.8 −3.6 9.2 −8.9 −6.3 2.6 BV
Nausea and  
vomiting  
symptoms
−9.1 −8.4 0.6 −10.1 −8.2 1.9 −14.5 −6.0 8.5 −20.2 −5.7 14.5 −14.7 −7.2 7.5 BV
Appetite loss  
symptoms
−10.3 −6.1 4.2 −13.1 −3.9 9.2 −17.1 0.5 17.6 −20.8 0.0 20.8 −20.8 −2.7 18.1 BV
Constipation  
symptoms
−7.4 −3.1 4.3 −10.5 1.7 12.2 −5.3 0.5 5.8 −5.1 2.7 7.7 −8.0 1.8 9.8 BV
QLQ-LC13 Pain in arm  
or shoulder  
symptoms
8.5 3.5 −5.0 8.2 −1.7 −9.9 0.0 −5.2 −5.2 9.7 −1.3 −11.0 12.5 0.0 −12.5 BV + P
Alopecia  
symptoms
2.0 1.9 0.0 −3.5 1.3 4.8 −7.9 −1.0 6.9 −12.5 −8.7 3.8 −14.7 −10.8 3.9 BV
Peripheral  
neuropathy  
symptoms
−0.5 4.7 5.2 4.1 9.5 5.4 4.5 12.0 7.5 −4.3 16.7 21.0 2.8 9.9 7.1 BV
Changes in mean scores relative to corresponding premaintenance baseline levels are shown. Bold font indicates a clinically meaningful difference between trial arms in change of 
mean scores relative to premaintenance baseline levels.
aDifference between trial arms (change in mean BV + P score relative to premaintenance baseline minus the change in BV score relative to premaintenance baseline).
BV, bevacizumab; EORTC, European Organisation for Research and Treatment of Cancer; MTC, maintenance cycle; P, pemetrexed; QLQ-C30, Quality of Life Questionnaire Core 
30; QLQ-LC13, Quality of Life Lung Cancer–Specific Module.
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in ECOG PS at preinduction baseline may be reflected as a 
slightly higher mean physical functional score at preinduction 
and premaintenance baseline assessments. At premaintenance 
assessment, however, most scores, along with ECOG PS, were 
similar between arms. It is important to note that induction-
phase PROs reported here were from patients achieving PR 
or standard deviation after induction therapy (a criterion for 
receiving maintenance therapy) and are not those of the entire 
ITT population at preinduction baseline.
During maintenance, mean scores for global health 
and most functional scales were similar in both arms, with 
largely overlapping standard deviation values. Role function 
and social function scores slightly favored the bevacizumab 
arm, and the symptoms scores for pain in arm or shoulder 
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FIGURE 1.  Mean scores, with stan-
dard deviations, for selected patient-
reported European Organisation for 
Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire 
Core 30 (QLQ-C30) functional scales 
in AVAPERL, from preinduction base-
line to maintenance cycle 11. Cy, 
cycle; Ind, induction; MTC, mainte-
nance cycle; Preind, preinduction; 
PreMTC, premaintenance.
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slightly favored the bevacizumab-plus-pemetrexed arm. 
Fatigue symptoms decreased after induction in both main-
tenance arms. The largest differences in symptom scores 
between arms were for appetite loss, with postinduction 
scores remaining stable for patients in the bevacizumab-
plus-pemetrexed arm but decreasing noticeably for patients 
treated with bevacizumab alone. Similarly, patient-reported 
nausea/vomiting symptoms decreased relative to premain-
tenance levels in both maintenance arms, but improvements 
were more pronounced for patients in the bevacizumab-
alone arm.
Limitations of this analysis include the consistently 
lower rate of compliance with HRQOL assessment in the 
bevacizumab-alone arm during maintenance treatment. 
These numbers seem to reflect lower questionnaire distribu-
tion rates rather than a reduced likelihood of patients in that 
arm completing the questionnaire. With this caveat in mind 
and despite the higher incidence of grade ≥3 adverse events 
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FIGURE 2.  Mean scores, with 
SDs, for selected patient reported 
European Organisation for Research 
and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire Core 
30 (QLQ-C30) and Quality of Life 
Lung Cancer–Specific Module 
(QLQ-LC13) symptom subscales in 
AVAPERL from preinduction baseline 
to maintenance cycle 11. Cy, cycle; 
Bev, bevacizumab; Ind, induction; 
MTC, maintenance cycle; Pem, 
pemetrexed; Preind, preinduction; 
PreMTC, premaintenance.
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seen in the bevacizumab-plus-pemetrexed arm for the major-
ity of subscales assessed, differences between trial arms were 
minor.23,25 Thus, AVAPERL patients treated with bevacizumab 
plus pemetrexed received a clinical benefit in PFS from ran-
domization (7.4 versus 3.7 months; HR = 0.48; p < 0.001) 
without reporting an adverse effect on HRQOL, while show-
ing durability of disease symptom control, thereby supporting 
the value of this maintenance phase regimen as an important 
treatment option for patients with advanced or metastatic non-
squamous NSCLC.
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